(Reuters) – GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion.
(Reporting by Aatrayee Chatterjee in Bengaluru)
